EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics

Yucui Zhao, Shixiao Zhu, Yingling Dong, Tian Xie, Zhiqiang Chai, Xiumei Gao, Yongna Dai, Xiaoying Wang

Biomolecules · 2024

DOI: 10.3390/biom14121643 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Yucui Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Ti…. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Microbiome, Brain-Gut Axis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 242 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xiumei Gao, National Natural Science Foundation of China, National Nature Key Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID) characterized by chronic or recurrent gastrointestinal symptoms without organic changes, and it is also a common disorder of gut–brain interaction (DGBIs).. The symptoms of IBS not only affect the quality of life for individual patients but also place a significant burden on global healthcare systems. The lack of established and universally applicable biomarkers for IBS, along with the substantial variability in symptoms and progression, presents challenges in developing effective clinical treatments. In recent years, preclinical and clinical studies have linked the pathogenesis of IBS to alterations in the composition and function of the intestinal microbiota. Within the complex microbial community of the gut, intricate metabolic and spatial interactions occur among its members and between microbes and their hosts. Amid the multifaceted pathophysiology of IBS, the role of intestinal microenvironment factors in symptom development has become more apparent. This review aims to delve into the changes in the composition and structure of the gut microbiome in individuals with IBS. It explores how diet-mediated alterations in intestinal microbes and their byproducts play a role in regulating the pathogenesis of IBS by influencing the “brain-gut” axis, intestinal barrier function, immune responses, and more. By doing so, this review seeks to lay a theoretical foundation for advancing the development of clinical therapeutics for IBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeGastrointestinal MicrobiomeBrain-Gut AxisHumansAnimals

Stichwörter der Autor:innen

IBSbrain–gut axisdiet-mediatedgut microbiomeimmune responses

Autor:innen und Institutionen

  • Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
  • School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
  • State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.

Förderung

  • Xiumei Gao
  • National Natural Science Foundation of China
  • National Nature Key Research and Development

Zitieren

APA

Zhao, Y., Zhu, S., Dong, Y., Xie, T., Chai, Z., Gao, X., Dai, Y., & Wang, X. (2024). The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics. Biomolecules. https://doi.org/10.3390/biom14121643

Vancouver

Zhao Y, Zhu S, Dong Y, Xie T, Chai Z, Gao X, et al. The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics. Biomolecules. 2024. doi:10.3390/biom14121643

BibTeX
@article{Zhao2024,
  author = {Zhao, Yucui and Zhu, Shixiao and Dong, Yingling and Xie, Tian and Chai, Zhiqiang and Gao, Xiumei and Dai, Yongna and Wang, Xiaoying},
  title = {The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14121643}
}
Kostenlos starten →